PolyPid (PYPD) director discloses stock options on 17,456 shares

Rhea-AI Filing Summary

PolyPid Ltd. director Story Brooke reported an initial holding of stock options on Ordinary Shares. The options cover 17,456 underlying Ordinary Shares at an exercise price of $4.01 per share and expire on February 4, 2036. According to the footnote, these options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025, continuing through December 11, 2029.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Story Brooke

Role Director

Type	Security	Shares	Price	Value
holding	Stock option (right to buy)	--	--	--

Holdings After Transaction: Stock option (right to buy) — 17,456 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Story Brooke

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	03/11/2026	02/04/2036	Ordinary Shares	17,456(1)	$4.01	D

Explanation of Responses:

1. The options were granted on February 4, 2026 and vest on a quarterly basis beginning December 11, 2025 until December 11, 2029.

	/s/ Brooke Story	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does Story Brooke report in PolyPid (PYPD)?

Story Brooke, a director of PolyPid, reports holding stock options on 17,456 underlying Ordinary Shares. These options give the right to buy shares at a fixed exercise price, reflecting an equity-based component of Brooke’s relationship with the company.

What are the key terms of Story Brooke’s PolyPid stock options?

The stock options relate to 17,456 underlying Ordinary Shares with a $4.01 exercise price and a February 4, 2036 expiration. They were granted on February 4, 2026 and vest quarterly from December 11, 2025 through December 11, 2029.

Does Story Brooke’s Form 3 show any PolyPid share purchases or sales?

The Form 3 shows only a stock option holding, with no reported share purchases or sales. It is an initial statement of beneficial ownership, listing existing derivative equity interests rather than new market transactions in PolyPid shares.

Is Story Brooke’s ownership in PolyPid held directly or indirectly?

The filing identifies the stock option position as held directly by Story Brooke. The ownership code is marked as direct, and there are no footnotes indicating that an external entity, trust, or partnership holds voting or investment authority.

How long will Story Brooke’s PolyPid stock options remain exercisable?

The options expire on February 4, 2036, giving a multi-year window to exercise the right to buy 17,456 Ordinary Shares at $4.01. Vesting occurs quarterly from December 11, 2025 through December 11, 2029 before full exercisability is reached.